22 January 2002
Intel Named Technology Partner for Singapore's Biomedical Sciences Initiative
SINGAPORE, Jan. 22, 2002 - Intel today signed a Memorandum of Understanding (MOU) with Bioinformatics Institute (BII), an institute funded by Singapore's Agency for Science, Technology and Research (A*STAR), to become a technology partner for the government's biomedical sciences initiative. The agreement was signed between Dr Gunaretnam Rajagopal, Acting Director, the BioInformatics Institute, and Christian Morales, General Manager, Asia-Pacific, Intel Semiconductor Limited. As part of the agreement, Intel will provide BII with a range of services, including early access to certain Intel technologies, advanced training of selected staff from leading research institutes, and porting consultancy to help accelerate Singapore's multiple biotechnology programs. The BII will evaluate the implementation of the Intelâ Itaniumä processor family as one of the potential platforms for the Biomedical Grid in Singapore. "We applaud Singapore's biomedical sciences initiative for its vision to build a biomedical sciences hub," said Mr Morales. "Like many of the world's leading research institutes, BII acknowledges the value of cutting edge technology such as powerful Itanium-based systems, which deliver superior floating-point performance, memory performance, and critical support for large data sets." Said Professor Louis Lim, Executive Director of the Biomedical Research Council, Agency for Science, Technology and Research, "Biomedical Sciences relies heavily on information science. It is therefore important to have an excellent IT infrastructure to support and sustain biomedical research activity in Singapore. We are therefore honoured to have Intel as one of our technology partners to develop state-of-the-art computing infrastructure to support the growth of the industry." Singapore is well positioned to be a biomedical sciences hub because of its excellent business environment, world-class intellectual property rights protection, conducive regulatory infrastructure and extensive pool of research talent. Intel believes that the high demand for biomedical sciences research and development will be a major driver of computing innovation throughout the next decade, and the company is well positioned to provide the technology building blocks to the dynamic biomedical sciences industry. The Intel Itanium processor family addresses the requirements of scientific researchers, including superior floating-point performance, memory performance, and support for large data sets. Several leading research institutions have already begun to deploy Itanium-based systems, including The National Center for Supercomputing Applications (NCSA), the Cornell Theory Center and the European Organization for Nuclear Research (CERN). About Intel Intel, the world's largest chip maker, is also a leading manufacturer of computer, networking and communications products. Additional information about Intel is available at About A*STAR Agency for Science, Technology and Research (A*STAR) formerly known as National Science and Technology Board, aims to foster world class scientific research and talent for a vibrant knowledge-based Singapore. A*STAR is organised into four arms: the Biomedical Research Council (BMRC), the Science & Engineering Research Council (SERC), a Corporate Planning and Administration Division (CPAD) and the agency's commercialisation arm, Exploit Technologies Pte Ltd. For more information on A*STAR, kindly refer to A*STAR. About Bioinformatics Institute The Bioinformatics Institute (BII), an institute funded by A*STAR, has been set up to be the focus of research and teaching in bioinformatics in Singapore. Dr Gunaretnam Rajagopal, formerly the Assistant Director of Research from the Cavendish Laboratory in UK's Cambridge University, was appointed as the Acting Director of the BII from July 2001. For details on Bioinformatics Institute and the BioMedical Grid, please refer to BII. Intel and Itanium are registered trademarks of Intel Corporation or its subsidiaries in the United States and other countries. Third party marks and brands are property of their respective holders.

Feedback Login Site Map